Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics
This trial is active, not recruiting.
|Treatment||long- and intermediate- acting insulins|
|Sponsor||Biologics & Biosimilars Collective Intelligence Consortium|
|Start date||January 2011|
|End date||September 2015|
|Trial size||100000 participants|
|Trial identifier||NCT02922179, BBCIC Insulins|
Over the past 40 years, new types of insulins have been marketed to mirror the effect of endogenous insulin. With the existing long-acting insulin product patents expiring and the FDA approval of new biosimilar and innovator insulins, adults with diabetes and their physicians will have additional therapeutic options. This observational study will describe the patient characteristics of new and existing users of long-acting or intermediate acting insulins with and without oral anti-diabetic agents (OAD) as well as acute hypoglycemic episodes, acute cardiac events, and A1C measures. The Biologic and Biosimilars Collective Intelligence Consortium (BBCIC) will use the findings from this descriptive analysis to design a comparative study evaluating the real-world effectiveness and safety of biosimilar and innovator insulins.
serious hypoglycemic events
time frame: Anticipated completion January 2017
Serious cardiac events
time frame: Anticipated completion January 2017
Female participants at least 18 years old.
Inclusion Criteria: - Individuals with baseline period of 183 days with continuous medical and pharmacy coverage preceding the first prescription fill - new and current users of the following exposures - Long-acting insulin (insulin detemir, glargine) alone or with metformin (LAI) - Long-acting insulin (insulin detemir, glargine) plus rapid/short acting insulin (with or without metformin) (LAI+R) - Long-acting insulin (insulin detemir, glargine) plus second-generation sulfonylurea agent (Glimepiride, Glipizide, Glipizide/Metformin, Glyburide, Glyburide/Metformin) (with or without metformin) (LAI+sulfa) - NPH insulin (Humulin, Novolin) alone or with metformin (NPH) - NPH insulin (Humulin, Novolin) plus rapid/short acting insulin (with or without metformin) (NHP+R) - NPH insulin (Humulin, Novolin) plus second-generation sulfonylurea agent (Glimepiride, Glipizide, Glipizide/Metformin, Glyburide, Glyburide/Metformin (with or without metformin) (NPH + sulfa) Exclusion Criteria: - Adult patients with diabetes with health insurance evidence of insulin pumps and/ or insulin pump supplies, gestational diabetes, liver disorders, dialysis, end-stage renal disease (ESRD), amputations, hemoglobinopathy, hemolytic anemia, or sickle cell anemia or transfusion - Emergency Department (ED) visit for hypoglycemia; hospitalization or ED visit for cardiovascular event (stroke, acute myocardial infarction, unstable angina or diagnosis consistent with unstable angina -- i.e., occlusion without infarction or coronary insufficiency). - Adult patients with diabetes on any other insulins except cohort insulins (i.e., rapid/short unless in combinations above).* - Adult patients with diabetes on first-generation sulfonylureas, Dipeptidyl peptidase-4 (DPP4), Glucagon-like Peptide (GLP), Sodium-glucose cotransporter-2 (SGLT-2) or Thiazolidinediones (TZD) agents, alone or in combination with cohort defining drugs*: - First generation sulfonylurea agents (chlorpropamide, tolazamide ) - TZDs (pioglitazone, pioglitazone/metformin, rosiglitazone, rosiglitazone/metformin - DPP4s (sitagliptin, saxagliptin, linagliptin, alogliptin) - GLP1 (exenatide, liraglutide, dulaglutide) - SGLT-2 (empagliflozin, canagliflozin, dapagliflozin)
|Official title||Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics|
|Principal investigator||Dan Kent, PharmD,CDE|
|Description||Additional information: This protocol was designed as a descriptive analysis, not to support a hypothesis. This information is being provided to the public in the interest of transparency and for demonstrating the BBCIC's Distributed Research Network's (DRN) ability to define exposures, outcomes, covariates and confounders. When published, the report will caution that the protocol does not support any ability to compare safety or effectiveness but instead is to be used only to explore the feasibility of future, more detailed comparative analyses and to better understand the capabilities of the BBCIC project. Further, the report will caution that information from this protocol should not affect use of the medical products described in any way and the fact that the BBCIC is performing this descriptive analysis in no way suggests there is a safety or effectiveness issue with any of the products described.|
Call for more information